• Product NameRecombinant Human Bone Morphogenetic Protein 7
• Host SpeciesEscherichia coli.
• Purification> 95 % by SDS-PAGE and HPLC analyses.
• Biological ActivityData is not available.
• EndotoxinLess than 1 EU/ug of rHuBMP-7 as determined by LAL method.
• Alternative Names    OP-1
• UniprotP18075
• Gene ID655
• Calculated MW Approximately 15.7 kDa, a monomeric, non-glycosylated polypeptide chain containing 139 amino acids.
• Target Sequence STGSKQRSQN RSKTPKNQEA LRMANVAENS SSDQRQACKK HELYVSFRDL GWQDWIIAPE GYAAYYCEGE CAFPLNSYMN ATNHAIVQTL VHFINPETVP KPCCAPTQLN AISVLYFDDS SNVILKKYRN MVVRACGCH
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in 30 % acetonitrile, 0.1 % TFA.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Bone Morphogenetic Protein 7 is one of the BMPs, some of which belong to the TGF-beta superfamily (BMP2-7). There are more than thirteen BMPs have been discovered nowadays and they are involved in inducing cartilage and bone formation. BMP-7 is mainly expressed in kidney and bladder. It is also present in developing eyes, brain and ear during embryogenesis. BMP-7 also named osteogenic protein-1 (OP-1) is a potent osteoinductive cytokine and plays role in osteoblast differentiation, SMAD1 production and renal development and repair. Human BMP-7 is synthesized with a signal sequence (29 a.a.), a propeptide (263 a.a.), and a growth factor domain (139 a.a.). The growth factor domain of human BMP-7 shares 98 % a.a. sequence identity with mouse and rat BMP-7.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting